The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58 respectively) Within ...

Adults receiving tirzepatide lost more weight and had a greater decline in waist circumference than those receiving semaglutide. The proportion of adults experiencing adverse events was similar in ...

This translated to a loss of 22.8 kg in the tirzepatide-treated patients versus 15.0 kg in those who received semaglutide. David Horner, MD, PhD (Copenhagen University Hospital, Denmark), who wasn’t ...

In the 72-week trial—led by an investigator at Weill Cornell Medicine and NewYork-Presbyterian and conducted with the University of Texas McGovern Medical School, the David Geffen School of ...

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy ...

MALAGA, Spain—Patients with obesity treated with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy; Novo Nordisk) can achieve weight loss in the real world similar to what has ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...